JP2022512684A - B7h3シングルドメイン抗体およびその治療用組成物 - Google Patents

B7h3シングルドメイン抗体およびその治療用組成物 Download PDF

Info

Publication number
JP2022512684A
JP2022512684A JP2021520197A JP2021520197A JP2022512684A JP 2022512684 A JP2022512684 A JP 2022512684A JP 2021520197 A JP2021520197 A JP 2021520197A JP 2021520197 A JP2021520197 A JP 2021520197A JP 2022512684 A JP2022512684 A JP 2022512684A
Authority
JP
Japan
Prior art keywords
seq
nos
binding
amino acid
polypeptide construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021520197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512684A5 (cg-RX-API-DMAC7.html
Inventor
ブレンダン ピー. エッケルマン
マイケル ディー. カプラン
ケイトリン エム. ウィリス
カイル エス. ジョーンズ
アンジェリカ エヌ. サナブリア
シドニー エー. バーンズ
マーガレット イー. ヘア
ジョーン シー. ティマー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aatd Inc
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of JP2022512684A publication Critical patent/JP2022512684A/ja
Publication of JP2022512684A5 publication Critical patent/JP2022512684A5/ja
Priority to JP2024148159A priority Critical patent/JP2024167342A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2021520197A 2018-10-11 2019-10-09 B7h3シングルドメイン抗体およびその治療用組成物 Ceased JP2022512684A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024148159A JP2024167342A (ja) 2018-10-11 2024-08-30 B7h3シングルドメイン抗体およびその治療用組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862744640P 2018-10-11 2018-10-11
US62/744,640 2018-10-11
US201962832274P 2019-04-10 2019-04-10
US62/832,274 2019-04-10
US201962877812P 2019-07-23 2019-07-23
US62/877,812 2019-07-23
PCT/US2019/055427 WO2020076970A1 (en) 2018-10-11 2019-10-09 B7h3 single domain antibodies and therapeutic compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024148159A Division JP2024167342A (ja) 2018-10-11 2024-08-30 B7h3シングルドメイン抗体およびその治療用組成物

Publications (2)

Publication Number Publication Date
JP2022512684A true JP2022512684A (ja) 2022-02-07
JP2022512684A5 JP2022512684A5 (cg-RX-API-DMAC7.html) 2022-10-17

Family

ID=68318988

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021520197A Ceased JP2022512684A (ja) 2018-10-11 2019-10-09 B7h3シングルドメイン抗体およびその治療用組成物
JP2024148159A Pending JP2024167342A (ja) 2018-10-11 2024-08-30 B7h3シングルドメイン抗体およびその治療用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024148159A Pending JP2024167342A (ja) 2018-10-11 2024-08-30 B7h3シングルドメイン抗体およびその治療用組成物

Country Status (7)

Country Link
US (1) US20230124851A1 (cg-RX-API-DMAC7.html)
EP (1) EP3864044A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022512684A (cg-RX-API-DMAC7.html)
CN (1) CN113166261A (cg-RX-API-DMAC7.html)
CA (1) CA3115082A1 (cg-RX-API-DMAC7.html)
TW (1) TW202028246A (cg-RX-API-DMAC7.html)
WO (1) WO2020076970A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Dll3シングルドメイン抗体およびその治療用組成物
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
EP4097129A1 (en) * 2020-01-29 2022-12-07 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
WO2022002038A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 免疫细胞衔接器多特异性结合蛋白及其制备和应用
EP4545569A3 (en) * 2020-06-30 2025-10-08 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
CN111662384B (zh) 2020-06-30 2021-04-09 广州百暨基因科技有限公司 抗b7h3抗体及其应用
TWI818276B (zh) * 2020-06-30 2023-10-11 大陸商和鉑醫藥(上海)有限責任公司 Fab-HCAb結構的結合蛋白
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
CA3215429A1 (en) * 2021-04-06 2022-10-13 Unicet Biotech Co. Llc Methods to improve stability of virus transduction of .gamma..delta. t cells and applications thereof
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
AU2022301099A1 (en) * 2021-07-01 2024-02-15 Ningbo T-Maximum Biopharmaceuticals Co., Ltd. Antigen-binding polypeptide targeting b7h3 and application thereof
CN118556083A (zh) * 2021-10-12 2024-08-27 乐普创一生物科技(上海)有限公司 具有改善的治疗指数的靶向cd3的t细胞衔接器
CN113980143B (zh) * 2021-11-02 2023-04-25 深圳先进技术研究院 靶向cd276的嵌合抗原受体、嵌合抗原受体t细胞及制备方法和制药应用
JPWO2023100944A1 (cg-RX-API-DMAC7.html) * 2021-12-01 2023-06-08
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
JP2025526677A (ja) * 2022-08-08 2025-08-15 ティクヴァ アロセル プライベート リミテッド B7-h3抗原結合性分子
WO2024061297A1 (en) * 2022-09-22 2024-03-28 Shanghai Henlius Biotech , Inc. Anti-b7h3 antibodies, multispecific antibodies and methods of use
JP2025531402A (ja) * 2022-09-22 2025-09-19 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗b7h3抗体及び使用方法
TW202428608A (zh) * 2022-12-29 2024-07-16 英屬開曼群島商百濟神州有限公司 抗b7h3抗體以及其使用方法
TW202430568A (zh) * 2022-12-29 2024-08-01 英屬開曼群島商百濟神州有限公司 抗b7h3抗體以及其使用方法
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
CN118829656B (zh) * 2023-12-01 2026-04-24 苏州智核生物医药科技有限公司 B7h3结合多肽及其用途
TW202528354A (zh) * 2024-01-03 2025-07-16 中國商北京泰德製藥股份有限公司 B7-h3結合蛋白及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025157244A1 (zh) * 2024-01-25 2025-07-31 山东先声生物制药有限公司 抗b7h3抗体及其应用
CN118702816B (zh) * 2024-06-03 2025-03-28 内蒙古正德缘生物科技有限责任公司 一种nk细胞及其在抗肿瘤治疗中的应用
WO2026086929A1 (zh) * 2024-10-24 2026-04-30 北京科诺信诚科技有限公司 靶向人b7h3的纳米抗体及其应用
WO2026128367A1 (en) * 2024-12-09 2026-06-18 Y-Mabs Therapeutics, Inc. Tumor binding molecules and the use thereof for the diagnosis and treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517844A (ja) * 2011-05-21 2014-07-24 マクロジェニクス,インコーポレーテッド ヒト及び非ヒトcd3に結合可能なcd3結合分子
WO2016192613A1 (zh) * 2015-06-01 2016-12-08 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
JP2017532952A (ja) * 2014-08-27 2017-11-09 メモリアル スローン−ケタリング キャンサー センター 抗体、組成物および使用
JP2017536829A (ja) * 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3および腫瘍抗原に結合するヘテロ二量体抗体
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3414831A1 (de) 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
DE3536939A1 (de) 1985-10-17 1987-04-23 Hoechst Ag Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE4036856C1 (cg-RX-API-DMAC7.html) 1990-11-19 1992-05-27 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5770191A (en) 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
FR2822845B1 (fr) 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823763A1 (fr) 2001-04-18 2002-10-25 Genodyssee Nouveaux polynucleotides et polypeptides de l'interferon alpha 6
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
FR2824333B1 (fr) 2001-05-03 2003-08-08 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
FR2825102B1 (fr) 2001-05-23 2003-08-29 Genodyssee Nouveaux polynucleotides et polypeptides de l'interferon alpha 14
FR2825716B1 (fr) 2001-06-11 2004-09-24 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 7
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
CA2498284A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP3803790B2 (ja) 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
AU2006291005A1 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
AU2008329518A1 (en) 2007-11-27 2009-06-04 Viventia Biotechnologies Inc. Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EP2703486B1 (en) * 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US20150239991A1 (en) 2012-09-25 2015-08-27 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
CA2889951C (en) 2012-11-02 2023-04-18 Zymeworks Inc. Crystal structures of heterodimeric fc domains
EA032681B1 (ru) 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US9703815B2 (en) 2012-12-17 2017-07-11 Salesforce.Com, Inc. Third party files in an on-demand database service
KR20150095684A (ko) 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
EP3149040A1 (en) * 2014-05-29 2017-04-05 Spring Bioscience Corporation Anti-b7-h3 antibodies and diagnostic uses thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016019300A1 (en) * 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
ES2935274T3 (es) 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
EP3247407A4 (en) 2015-01-21 2018-08-22 Inhibrx LP Non-immunogenic single domain antibodies
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3325512B1 (en) 2015-07-23 2023-09-06 Inhibrx, Inc. Multivalent and multispecific gitr-binding fusion proteins
JP2018523686A (ja) 2015-08-17 2018-08-23 マクロジェニクス,インコーポレーテッド B7‐h3及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
IL300122A (en) * 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
JP7328761B2 (ja) 2016-01-11 2023-08-17 インヒブルクス インコーポレイテッド 多価多重特異性ox40結合融合タンパク質
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
WO2018027025A1 (en) 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN109843927B (zh) * 2017-03-06 2022-06-21 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
EP3732199A1 (en) 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
TW202010757A (zh) * 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517844A (ja) * 2011-05-21 2014-07-24 マクロジェニクス,インコーポレーテッド ヒト及び非ヒトcd3に結合可能なcd3結合分子
JP2017532952A (ja) * 2014-08-27 2017-11-09 メモリアル スローン−ケタリング キャンサー センター 抗体、組成物および使用
JP2017536829A (ja) * 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3および腫瘍抗原に結合するヘテロ二量体抗体
WO2016192613A1 (zh) * 2015-06-01 2016-12-08 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MA, WANRU ET AL., CANCER MEDICINE, vol. Vol. 7, Issue 10, JPN6023033915, 25 September 2018 (2018-09-25), pages 5167 - 5177, ISSN: 0005313919 *

Also Published As

Publication number Publication date
EP3864044A1 (en) 2021-08-18
WO2020076970A1 (en) 2020-04-16
CA3115082A1 (en) 2020-04-16
JP2024167342A (ja) 2024-12-03
US20230124851A1 (en) 2023-04-20
TW202028246A (zh) 2020-08-01
CN113166261A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
JP7611820B2 (ja) Dll3シングルドメイン抗体およびその治療用組成物
JP7789002B2 (ja) Cd28シングルドメイン抗体ならびにその多価および多重特異性の構築物
TWI856030B (zh) Pd-1單一域抗體及其之治療組合物
JP2024167342A (ja) B7h3シングルドメイン抗体およびその治療用組成物
TWI863932B (zh) 5t4單域抗體及其治療性組合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221006

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241021

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241029

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241108

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250114

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250522